MoneyWorks4Me

USFDA retains OAI status for Indoco’s Goa Plant

24 Apr 2019 Evaluate

The United States Food and Drug Administration (USFDA) has retained the Official Action Indicated (OAI) status for Goa Plant - I (Finished Dosages Facility) of Indoco Remedies. The facility was inspected by the USFDA in January 2019. The plant currently supplies against one approved ANDA and has four ANDAs pending for approval.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Peers
Company Name CMP
Sun Pharma. Inds. 1756.90
Dr. Reddys Labs. 1195.10
Cipla 1303.30
Lupin 1960.00
Zydus Lifesciences 1115.10
View more..